Frazier Life Sciences Management, L.P.: ARCUTIS BIOTHERAPEUTICS INC (ARQT): Quarterly 13F Position History
As of Q1 2026, Frazier Life Sciences Management, L.P. reported 9,874,511 shares of ARCUTIS BIOTHERAPEUTICS INC (ARQT), worth $232.6M and representing 6.0% of its 13F equity book. The position first appeared in Q1 2022 and has been disclosed across 17 13F-HR filings in Pactolio's tracked window.
- 9,874,511Shares Held (Latest Filing)
- $232.6MReported Market Value (Latest Filing)
- 6.0%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$54.1MQuarter-over-Quarter Value Change
- 9,874,511Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 17 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 9,874,511 | 0 | — | $232.6M | 6.0% | $23.6 |
| Q4 2025 | 9,874,511 | 0 | — | $286.8M | 7.7% | $29.0 |
| Q3 2025 | 9,874,511 | 0 | — | $186.1M | 5.6% | $18.9 |
| Q2 2025 | 9,874,511 | +1,089,227 | +12.4% | $138.4M | 5.5% | $14.0 |
| Q1 2025 | 8,785,284 | 0 | — | $137.4M | 6.3% | $15.6 |
| Q4 2024 | 8,785,284 | 0 | — | $122.4M | 5.1% | $13.9 |
| Q3 2024 | 8,785,284 | 0 | — | $81.7M | 3.3% | $9.3 |
| Q2 2024 | 8,785,284 | 0 | — | $81.7M | 3.8% | $9.3 |
| Q1 2024 | 8,785,284 | +21,052 | +0.2% | $87.1M | 3.7% | $9.9 |
| Q4 2023 | 8,764,232 | +80,000 | +0.9% | $28.3M | 1.5% | $3.2 |
| Q3 2023 | 8,684,232 | 0 | — | $46.1M | 3.1% | $5.3 |
| Q2 2023 | 8,684,232 | 0 | — | $82.8M | 4.9% | $9.5 |
| Q1 2023 | 8,684,232 | 0 | — | $95.5M | 6.9% | $11.0 |
| Q4 2022 | 8,684,232 | 0 | — | $128.5M | 8.0% | $14.8 |
| Q3 2022 | 8,684,232 | +250,000 | +3.0% | $166.0M | 12.8% | $19.1 |
| Q2 2022 | 8,434,232 | 0 | — | $179.7M | 17.0% | $21.3 |
| Q1 2022 | 8,434,232 | — | — | $162.4M | 13.8% | $19.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Frazier Life Sciences Management, L.P. first disclose a ARQT position in 13F-HR filings?
Frazier Life Sciences Management, L.P. first reported ARCUTIS BIOTHERAPEUTICS INC (ARQT) on its 13F-HR filing for the period ending 2022-03-31 (Q1 2022). The position has appeared on 17 reported quarters within Pactolio's tracked window.
What was Frazier Life Sciences Management, L.P.'s most recent quarter-over-quarter share-count change in ARQT?
Frazier Life Sciences Management, L.P. held the same 9,874,511 shares of ARQT between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Frazier Life Sciences Management, L.P.'s cost basis in ARQT?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.